{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:18:09Z","timestamp":1785795489538,"version":"3.56.0"},"reference-count":71,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background: Philadelphia-negative myeloproliferative neoplasms (MPN) are most prevalent in the older population (median age at the diagnosis is above 60 years) and rarely diagnosed in pediatrics. Thus, our knowledge about the clinical presentation, mutational status, and complications of MPNs in pediatrics is limited. Methods: The literature in English (PubMed, SCOPUS, and Google Scholar) was searched for studies, reviews, case series, and case reports of patients with Philadelphia-negative MPNs (including essential thrombocythemia, polycythemia vera, primary myelofibrosis, and profibrotic myelofibrosis) in the pediatrics age group (less than 18 years). Only studies that fulfilled WHO 2008 or 2016 criteria for MPNs were included. We aimed to describe the clinical characteristics, vascular and long-term complications, types of driver mutations, and treatment approaches in pediatric patients with MPNs. Results: We reviewed 33 articles of available published literature from 2008 to 2022 and collected data from a total of 196 patients of the pediatric population. Among the cohort of patients, 139 had essential thrombocythemia (ET), 20 had polycythemia vera (PV), and 37 had primary myelofibrosis (PMF). The median age at the time of diagnosis for each disease varied, with 8.8 years for ET, 10 years for PV, and 3.6 years for MF. There was a slight difference in gender prevalence between both gender groups and all three diseases. The presenting symptoms were not mentioned in more than 50% of studies. We found that JAK2 was the most prevalent among all mutations. Both bleeding and thrombosis were present equally in ET, with 9% of cases complicated by bleeding and 9% complicated by thrombosis. Hemorrhagic events did not occur in patients with PV; thrombosis in children with MF was also not found. The progression into AML occurred in two patients with PV and one with ET. Conclusion: Given the rarity of MPNs in pediatrics and their different characteristics compared with adults, we believe there is a need for unique diagnostic criteria to match the different molecular statuses in pediatrics. Based on our review, the incidence of MPN complications in pediatrics, including thrombotic events, hemorrhage, and leukemic transformation, differs from that in adults.<\/jats:p>","DOI":"10.3390\/diagnostics13030377","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T05:50:20Z","timestamp":1674107420000},"page":"377","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pediatric Philadelphia-Negative Myeloproliferative Neoplasms in the Era of WHO Classification: A Systematic Review"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1393-5302","authenticated-orcid":false,"given":"Abdulrahman F.","family":"Al-Mashdali","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Hamad Medical Corporation, Doha 3050, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmood B.","family":"Aldapt","sequence":"additional","affiliation":[{"name":"Department of Medicine, Unity Hospital, Rochester Regional Health, Rochester, NY 14626, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Rahhal","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hamad Medical Corporation, Doha 3050, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0760-9906","authenticated-orcid":false,"given":"Yousef M.","family":"Hailan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hamad Medical Corporation, Doha 3050, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israa","family":"Elhakeem","sequence":"additional","affiliation":[{"name":"Clinical Oncology, Hamad Medical Corporation, Doha 3050, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elrazi A.","family":"Ali","sequence":"additional","affiliation":[{"name":"One Brooklyn Health, Interfaith Medical Center, Internal Medicine Department, Brooklyn, NY 11213, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waail","family":"Rozi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hamad Medical Corporation, Doha 3050, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1144-8076","authenticated-orcid":false,"given":"Mohamed A.","family":"Yassin","sequence":"additional","affiliation":[{"name":"National Center for Cancer Care and Research, Department of Oncology, Hematology and BMT Section, Hamad Medical Corporation, Doha 3050, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s12308-015-0256-1","article-title":"Myeloproliferative Neoplasms in Children","volume":"8","author":"Hofmann","year":"2015","journal-title":"J. Hematop."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/MPH.0000000000001173","article-title":"Myeloproliferative Neoplasms in Children and Adolescents and Thrombosis at Unusual Sites: The Role of Driver Mutations","volume":"41","author":"Tafesh","year":"2019","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.3324\/haematol.2018.200832","article-title":"Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: A systematic review","volume":"104","author":"Ianotto","year":"2019","journal-title":"Haematologica"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11899-020-00571-8","article-title":"Myeloproliferative Neoplasms in Children, Adolescents, and Young Adults","volume":"15","author":"Kucine","year":"2020","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/jha2.39","article-title":"Clinical features of children with polycythemia vera, essential thrombocythemia, and primary myelofibrosis in Japan: A retrospective nationwide survey","volume":"1","author":"Ishida","year":"2020","journal-title":"EJHaem"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/pbc.21218","article-title":"Essential thrombocythemia in a child with elevated thrombopoietin concentrations and skeletal anomalies","volume":"50","author":"Robins","year":"2008","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/pbc.21730","article-title":"Frequency and clinical features of the JAK2 V617F mutation in pediatric patients with sporadic essential thrombocythemia","volume":"51","author":"Nakatani","year":"2008","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/MPH.0b013e3181b1ec9e","article-title":"JAK2V617F mutation-positive childhood essential thrombocythemia associated with cerebral venous sinus thrombosis","volume":"31","author":"Kurosawa","year":"2009","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3109\/08880018.2012.662712","article-title":"Spontaneous resolution of extreme thrombocytosis in 2 children","volume":"29","author":"Aviner","year":"2012","journal-title":"Pediatr. Hematol. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1007\/s12185-012-1193-8","article-title":"Two cases of pediatric essential thrombocythemia managed effectively with hydroxyurea","volume":"96","author":"Dua","year":"2012","journal-title":"Int. J. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"E52","DOI":"10.1002\/pbc.24500","article-title":"MPL W515L mutation in pediatric essential thrombocythemia","volume":"60","author":"Farruggia","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"66","DOI":"10.5144\/1658-3876.2012.66","article-title":"JAK2 mutation-negative essential thrombocythemia in a child presenting with cerebral venous thrombosis","volume":"5","author":"Khan","year":"2012","journal-title":"Hematol. Oncol. Stem. Cell"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3324\/haematol.2009.007542","article-title":"Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis","volume":"95","author":"Teofili","year":"2010","journal-title":"Haematologica"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/pbc.23409","article-title":"Mutations profile of polycythemia vera and essential thrombocythemia among Japanese children","volume":"59","author":"Ismael","year":"2012","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.3324\/haematol.2016.142935","article-title":"Genetic analysis of five children with essential thrombocytosis identified mutations in cancer-associated genes with roles in transcriptional regulation","volume":"101","author":"Kucine","year":"2016","journal-title":"Haematologica"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/MPH.0b013e3182278266","article-title":"Myelofibrosis: A cause of increased transfusion requirement in a child with \u03b2-thalassemia intermedia","volume":"34","author":"Nirupam","year":"2012","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s12288-014-0412-2","article-title":"Paediatric idiopathic myelofibrosis","volume":"30","author":"Saksena","year":"2014","journal-title":"Indian J. Hematol. Blood Transfus."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e199","DOI":"10.1097\/MPH.0b013e3182346cc5","article-title":"Allogeneic cord hematopoietic stem cell transplantation in an infant with primary myelofibrosis","volume":"34","author":"Shaikh","year":"2012","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/MPH.0b013e31829cdea0","article-title":"Idiopathic myelofibrosis in children: Primary myelofibrosis, essential thrombocythemia, or transient process?","volume":"35","author":"Slone","year":"2013","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5078","DOI":"10.1182\/blood-2012-12-475566","article-title":"The Thr224Asn mutation in the VPS45 gene is associated with the congenital neutropenia and primary myelofibrosis of infancy","volume":"121","author":"Stepensky","year":"2013","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"805","DOI":"10.3109\/09537104.2015.1041900","article-title":"Essential thrombocythemia with Mpl W515 K mutation in a child presenting with Budd-Chiari syndrome","volume":"26","author":"Tokgoz","year":"2015","journal-title":"Platelets"},{"key":"ref_23","first-page":"35","article-title":"Asymtomatic essential thrombocythemia in a child: A rare case report","volume":"7","author":"Vafaie","year":"2013","journal-title":"Int. J. Hematol. Oncol. Stem. Cell Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/MPH.0000000000000453","article-title":"JAK2+ Essential Thrombocythemia in a Young Girl With Budd-Chiari Syndrome: Diagnostic and Therapeutic Considerations When Adult Disease Strikes the Young","volume":"38","author":"Wigton","year":"2016","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/pbc.21910","article-title":"Unrelated stem cell transplant for infantile idiopathic myelofibrosis","volume":"52","author":"Domm","year":"2009","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1080\/09537104.2019.1704710","article-title":"Platelet function and blood coagulation system status in childhood essential thrombocythemia","volume":"31","author":"Polokhov","year":"2020","journal-title":"Platelets"},{"key":"ref_27","first-page":"634","article-title":"Paediatrics primary myelofibrosis and acute stroke: A rare presentation","volume":"67","author":"Mazher","year":"2017","journal-title":"J. Pak. Med. Assoc."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1097\/MPH.0000000000000641","article-title":"A Rare Case of Primary Myelofibrosis in a 14-Year-Old Patient With Congenital Asplenia","volume":"39","author":"Khan","year":"2017","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"243","DOI":"10.5001\/omj.2017.45","article-title":"Essential Thrombocythemia in a Two-year-old Child, Responsive to Hydroxyurea but Not Aspirin","volume":"32","author":"Aladily","year":"2017","journal-title":"Oman Med. J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1055\/s-0039-1679929","article-title":"Fulminant Essential Thrombocythemia Associated with Acquired Von Willebrand Syndrome and Bleeding Episodes in a 14-year-old Girl","volume":"39","author":"Schneider","year":"2019","journal-title":"Hamostaseologie"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e28183","DOI":"10.1002\/pbc.28183","article-title":"Essential thrombocythemia A retrospective case series","volume":"67","author":"Barg","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s10875-020-00778-7","article-title":"Infantile Myelofibrosis and Myeloproliferation with CDC42 Dysfunction","volume":"40","author":"Verboon","year":"2020","journal-title":"J. Clin. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e28994","DOI":"10.1002\/pbc.28994","article-title":"Polycythemia vera in a 2-year-old child with a JAK2 exon 12 deletion","volume":"68","author":"Kucine","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e28816","DOI":"10.1002\/pbc.28816","article-title":"Double L611S\/V617F JAK2 mutation in a child with erythrocytosis","volume":"68","author":"Lebecque","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s12098-020-03579-3","article-title":"JAK2V617F Exon-14 Mutation Driven Polycythemia Vera","volume":"88","author":"Archana","year":"2021","journal-title":"Indian J. Pediatr."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e28888","DOI":"10.1002\/pbc.28888","article-title":"Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia","volume":"68","author":"Kucine","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/ajh.23140","article-title":"Clinical, histopathologic, and genetic features of pediatric primary myelofibrosis--an entity different from adults","volume":"87","author":"DeLario","year":"2012","journal-title":"Am. J. Hematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/bjh.14061","article-title":"Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic\/myeloproliferative neoplasms in the United States, 2001\u20132012","volume":"174","author":"Srour","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1046\/j.1365-2141.2000.02239-7.x","article-title":"Incidence of essential thrombocythaemia in children","volume":"110","author":"Hasle","year":"2000","journal-title":"Br. J. Haematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/(SICI)1099-1069(199711)15:4<173::AID-HON610>3.0.CO;2-K","article-title":"Age and sex distributions of hematological malignancies in the U.K","volume":"15","author":"McNally","year":"1997","journal-title":"Hematol. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1182\/bloodadvances.2022007201","article-title":"Real-world study of children and young adults with myeloproliferative neoplasms: Identifying risks and unmet needs","volume":"6","author":"Sobas","year":"2022","journal-title":"Blood Adv."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: An international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1182\/blood-2011-08-371328","article-title":"Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: Clinical and biologic features, treatment, and long-term outcome","volume":"119","author":"Giona","year":"2012","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: Critical concepts and management recommendations from European LeukemiaNet","volume":"29","author":"Barbui","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_45","first-page":"17","article-title":"From efficacy to safety: A Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera","volume":"34","author":"Fruchtman","year":"1997","journal-title":"Semin. Hematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/pbc.20906","article-title":"Stem cell transplantation for polycythemia vera","volume":"50","author":"Reinhard","year":"2008","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1365-2141.2005.05764.x","article-title":"JAK2 mutation in essential thrombocythaemia: Clinical associations and long-term prognostic relevance","volume":"131","author":"Wolanskyj","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Bhuria, V., Baldauf, C.K., Schraven, B., and Fischer, T. (2022). Thromboinflammation in Myeloproliferative Neoplasms (MPN)-A Puzzle Still to Be Solved. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23063206"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"648090","DOI":"10.1155\/2015\/648090","article-title":"The Role of Reactive Oxygen Species in Myelofibrosis and Related Neoplasms","volume":"2015","author":"Hasselbalch","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Gutmann, C., Siow, R., Gwozdz, A.M., Saha, P., and Smith, A. (2020). Reactive Oxygen Species in Venous Thrombosis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21061918"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1056\/NEJMc1200349","article-title":"Germline JAK2 mutation in a family with hereditary thrombocytosis","volume":"366","author":"Mead","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/leu.2009.141","article-title":"Mutations of ASXL1 gene in myeloproliferative neoplasms","volume":"23","author":"Carbuccia","year":"2009","journal-title":"Leukemia"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis","volume":"332","author":"Cortelazzo","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1182\/blood.V99.5.1602","article-title":"Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia","volume":"99","author":"Tomer","year":"2002","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","article-title":"Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: The ANAHYDRET Study, a randomized controlled trial","volume":"121","author":"Gisslinger","year":"2013","journal-title":"Blood"},{"key":"ref_59","first-page":"1394","article-title":"Anagrelide-associated cardiomyopathy in polycythemia vera and essential thrombocythemia","volume":"89","author":"Jurgens","year":"2004","journal-title":"Haematologica"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/sj.leu.2400931","article-title":"Alfa-interferon in the treatment of essential thrombocythemia: Clinical results and evaluation of its biological effects on the hematopoietic neoplastic clone. Italian Cooperative Group on ET","volume":"12","author":"Sacchi","year":"1998","journal-title":"Leukemia"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mayocp.2011.11.001","article-title":"One thousand patients with primary myelofibrosis: The mayo clinic experience","volume":"87","author":"Tefferi","year":"2012","journal-title":"Mayo Clin. Proc."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1182\/blood-2009-08-238956","article-title":"Thrombosis in primary myelofibrosis: Incidence and risk factors","volume":"115","author":"Barbui","year":"2010","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.3324\/haematol.2010.025064","article-title":"Thrombosis in myelofibrosis: Prior thrombosis is the only predictive factor and most venous events are provoked","volume":"95","author":"Elliott","year":"2010","journal-title":"Haematologica"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/cncr.22021","article-title":"Palliative goals, patient selection, and perioperative platelet management: Outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic","volume":"107","author":"Mesa","year":"2006","journal-title":"Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1182\/blood-2013-11-536557","article-title":"Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study","volume":"123","author":"Guglielmelli","year":"2014","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: Revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Kamps, R., Brand\u00e3o, R.D., van den Bosch, B.J., Paulussen, A.D., Xanthoulea, S., Blok, M.J., and Romano, A. (2017). Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18020308"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Skov, V. (2020). Next Generation Sequencing in MPNs. Lessons from the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses. Cancers, 12.","DOI":"10.3390\/cancers12082194"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/13\/3\/377\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:10:30Z","timestamp":1760119830000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/13\/3\/377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,19]]},"references-count":71,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["diagnostics13030377"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics13030377","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,19]]}}}